CVRx securities fraud investigation after stock drop
Analysis based on 7 articles · First reported Aug 13, 2026 · Last updated Aug 19, 2026
CVRx's stock plummeted 59% following the disclosures, erasing substantial market value. The investigation and DOJ probe could lead to significant legal costs, penalties, and further reputational damage, potentially impacting the company's ability to raise capital and its long-term viability.
CVRx, a medical device company, disclosed on August 6, 2026, that it had received a Civil Investigative Demand from the U.S. Department of Justice in May 2026, cut its 2026 revenue guidance, and revealed significant deterioration in its sales force and a collapse in Medicare Advantage approval rates. The company's stock fell 59% on August 7, 2026. On August 10, 2026, CVRx terminated its Chief Revenue Officer, Robert John. Hagens Berman, a shareholder rights law firm, opened an investigation into potential securities law violations, focusing on whether CVRx misled investors about its sales force and reimbursement rates and whether the CRO termination was connected to the DOJ inquiry.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard